Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.66 per share, beating the Zacks Consensus Estimate of $2.52 per share. This compares to earnings of $2.55 per share a year ago.

Johnson & Johnson (JNJ) Q3 Earnings and Revenues Surpass Estimates

Archer-Daniels-Midland Company

Aflac

BHP Billiton

Cummins

Corteva Inc

Dominion Energy

Discover

Dow Inc

Con Ed

Elevance Health Inc

Emerson Electric

Fortune Brands Innovations Inc

FirstEnergy

W.W. Grainger

Intel

Nordstrom

Jackson Financial

KeyCorp

Kraft Heinz

Kroger

Lockheed Martin

LyondellBasell Industries

Dividend Income Summary: Lanny's September 2023 Summary

Johnson & Johnson (NYSE:JNJ) raised guidance after a strong third quarter which saw earnings beat expectations and its product pipeline advance. The New Brunswick (NYSE:BC), New Jersey-based pharmaceutical giant said in the third quarter sales rose 6.8% to $21.35 billion from $20.00 billion the year ahead of the FactSet consensus of $21.04 billion.

Johnson & Johnson ups guidance as earnings top forecasts

Shares of Johnson & Johnson JNJ, +0.43% rallied 0.8% in premarket trading Tuesday, after the drug maker and medical technology company reported third-quarter profit and sales that rose above expectations, amid strength in its MedTech business. Net earnings from continuing operations were $4.31 billion, or $1.69 a share, after $4.31 billion, or $1.62 a share, in the year-ago period.

J&J's stock rallies after profit and sales rise above expectations, full-year outlook increased

Johnson & Johnson on Tuesday raised its 2023 profit forecast, helped by resilient demand for its anti-inflammatory drug Stelara and recorded a $21 billion gain from the spin off of its consumer health unit.

J&J raises annual profit forecast on anti-inflammatory drug demand

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2023. “Johnson & Johnson delivered strong results and significant pipeline advances in the third quarter, providing a solid foundation for future sustained growth,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “With a sharpened focus on Innovative Medicine and MedTech solutions, Johnson & Johnson is innovating across the spectrum of healthcare and i.

Johnson & Johnson Reports Q3 2023 Results

Earnings: Analysts tracked by FactSet expect J&J JNJ, +0.43% to post per-share earnings of $2.52, down from $2.55 in the year-earlier period.

Johnson & Johnson earnings: What to expect

Johnson & Johnson is a defensive pick with a renewed focus on its pharmaceutical and medtech segments. The recent selloff in the stock has brought its valuation down to undervalued levels. Johnson & Johnson offers a safe 3.0% dividend yield and can provide peace of mind in challenging market conditions.

Johnson & Johnson: A Conservative High-Yield Dividend Aristocrat Buy

Until recently Johnson & Johnson (NYSE: JNJ ) stock was the most conservative investment you could make in the drugs space. It still is, but that's no longer a compliment.

Johnson & Johnson Stock: Is Now the Time to Sell?

Johnson & Johnson (NYSE:JNJ) is slated to report earnings before the market opens on Tuesday in what will be the company's first report since spinning off its consumer health division, Kenvue.  For its third quarter, JNJ is expected to post revenue of $21.04 billion and earnings of $2.51 per share, compared to revenue of $23.79 billion and earnings of $1.68 per share a year earlier.

Johnson & Johnson's 3Q earnings in spotlight next week following Kenvue split

J&J's (JNJ) third-quarter results are the first quarterly update for the new company after the Consumer Health spin-off.

J&J (JNJ) to Report Q3 Earnings, Its First After Unit Spin-Off

Amazon

Chevron

Floor & Decor Holdings

Coca-Cola

Visa

VeriSign

While targeting Warren Buffett stocks – that is, the securities under the holdings of conglomerate Berkshire Hathaway (NYSE: BRK-B ) – might not seem particularly exciting, the Oracle of Omaha may be offering the best guidance given the circumstances. Unlike other random bits of “information” you might find on the Internet, the legendary investor knows what he's talking about.

Beat the Market With These 7 Warren Buffett Stocks

Stocks have turned volatile in response to rising bond yields. High-quality dividend stocks could be a great way to ride out this rough patch.

2 No-Brainer Dividend King Stocks to Buy Right Now

McDonald's

PepsiCo

Pfizer

QUALCOMM

Schwab US Dividend Equity ETF

SPDR Portfolio Total Stock Market ETF

SPDR Portfolio S&P 500 High Dividend ETF

Target

T. Rowe Price Group

Texas Instruments

Vanguard High Dividend Yield ETF

Exxon Mobil

Bert and his wife received $3,570.87 in September dividend income. This was a 16.52% dividend increase compared to September 2022. The stock and ETF split in the month of September was 45% ETF to 55% stock. Through investment in DRIP and dividend increases, Bert saw his income grow significantly for some of his positions.

Bert's September Dividend Income Summary

Amgen

Bank of America

Blackrock Inc

ConocoPhillips

Goldman Sachs

MetLife

Altria

Morgan Stanley

NextEra Energy

Paychex

PNC Financial Services

There are 20 stocks on my high yield watchlist for October 2023. The majority of the stocks on my watchlist are undervalued based on dividend yield theory. An equally weighted portfolio of these stocks underperformed the Vanguard High Yield Dividend ETF by about 0.50% during the month of September.

High Yield Stock Watchlist - October 2023

News for Johnson & Johnson Stock (JNJ)